伊布替尼
威尼斯人
布鲁顿酪氨酸激酶
中止
慢性淋巴细胞白血病
医学
单克隆抗体
肿瘤科
临床试验
单克隆
CD20
联合疗法
内科学
酪氨酸激酶
免疫学
抗体
白血病
受体
作者
Kerry A. Rogers,Jennifer A. Woyach
出处
期刊:Hematology
[American Society of Hematology]
日期:2024-11-25
卷期号:2024 (1): 467-473
被引量:3
标识
DOI:10.1182/hematology.2024000571
摘要
Abstract Frontline therapy for chronic lymphocytic leukemia (CLL) has substantially advanced in the previous decade. While monotherapy with a Bruton's tyrosine kinase (BTK) inhibitor is an excellent option for many patients, combination therapies are of high clinical interest as they can induce deep responses and durable remissions, and in many cases allow discontinuation of therapy. There are several doublet therapies that are currently in clinical use. These include combinations of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or BCL2 inhibitors (venetoclax) with anti-CD20 monoclonal antibodies, and combinations of BTK and BCL2 inhibitors. While BTK inhibitors with anti-CD20 monoclonal antibodies still typically require indefinite therapy, combinations involving the BCL2 inhibitor venetoclax have allowed for successful therapy discontinuation. Triplets, which combine all 3 of these paradigms, are of interest especially for patients with higher-risk disease. While triplets have been mainly studied in single-arm trials with excellent outcomes, comparative data to doublets are limited. In this article, we outline the doublet and triplet regimens that have been evaluated in CLL as well as the data from trials comparing doublets and triplets.
科研通智能强力驱动
Strongly Powered by AbleSci AI